Navigation Links
Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Date:11/1/2010

ROCHESTER, N.Y., Nov. 1, 2010 /PRNewswire/ -- Vaccinex, Inc. announced today that it has been awarded three grants by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company's three lead therapeutic monoclonal antibodies, VX15, VX5 and VX35.  The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.  

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101101/NY92716LOGO)

Commenting on the grant awards, Dr. Maurice Zauderer, President & CEO, said, "We are very appreciative of the recognition and support provided by these awards for innovative Vaccinex projects that could advance the treatment of cancer and autoimmune diseases, and also provide significant economic benefits to our community."

The three different Vaccinex projects represent novel approaches to inhibit invasive tumor growth and to treat multiple sclerosis and other neurodegenerative diseases.  Vaccinex expects to begin clinical trials of its lead therapeutic antibodies in cancer and multiple sclerosis in early 2011.

Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.   Website: www.vaccinex.com.  


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Dr. Yong Shi awarded NSF grant
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
7. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
8. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
9. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
10. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
11. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017  Alkahest Inc. ("Alkahest"), a biotechnology company ... and other age-related conditions, announced today that Sam Jackson, ... Medical Officer. In this role, Dr. Jackson will ... Alkahest and serve on the Executive Leadership Team.  ... Executive Director at Dynavax, where he led the Drug ...
(Date:1/21/2017)... Cambridge, MA (PRWEB) , ... January 20, 2017 ... ... and scientific consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has ... to its expanding team of clinical and scientific consultants and contractors. This is ...
(Date:1/21/2017)... Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" ... useful molecular diagnostic tests and pathology services, today ... purchase agreement with three  institutional investors to purchase ... in a registered direct offering.  In a concurrent ... to the same investors warrants to purchase 855,000 ...
(Date:1/21/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, today presented data from two clinical studies ... American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ... In a Phase Ib/II study of napabucasin – ... stemness pathways by targeting STAT3 – colorectal cancer (CRC) ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new report ... 2022," projects that the global biometric technology market is expected to generate revenue of ... Continue Reading ... Allied ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... 5, 2017  SomaLogic announced today that it ... established by iCarbonX, the China ... "Global Digital Health Ecosystem that can define each ... individual,s biological, behavioral and psychological data, the Internet ... companies, SomaLogic will provide proteomics data and applications ...
Breaking Biology News(10 mins):